Method for concentrating and purifying recombinant autonomous parvovirus vectors designed for tumour-cell-targeted gene therapy.
Recent work has highlighted the use of parvoviruses as potential vectors for tumour-cell-targeted gene therapy. The oncotropic properties of the prototype strain of minute virus of mice (MVMp) suggest that this virus might be a useful vehicle for introducing selectively therapeutic genes, e.g. lymphokine or suicide genes, into tumour cells and preferentially expressing them. But the low titre of recombinant virus stocks (10(5)-10(6) infectious units per ml) and their high level of contamination by cell proteins make it practically impossible to evaluate their efficacy in in vivo systems. A technique is described for producing cellular contaminant-free stocks of recombinant virus particles, with titres up to 5 x 10(8) IU/ml.
Avalosse
B
B
Laboratory of Molecular Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Dupont
F
F
Spegelaere
P
P
Mine
N
N
Burny
A
A
D000818:Animals; D002478:Cells, Cultured; D002499:Centrifugation, Density Gradient; D003001:Cloning, Molecular / Q000379:methods*; D004591:Electrophoresis, Polyacrylamide Gel; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000302:isolation & purification*; D051379:Mice; D008915:Minute Virus of Mice / Q000235:genetics*; D009374:Neoplasms, Experimental / Q000628:therapy; D011995:Recombination, Genetic; D014162:Transfection